Cecilia Herbert - IShares Pharmaceuticals Independent Trustee
| IHE Etf | USD 65.91 0.55 0.84% |
Ms. Cecilia H. Herbert serves as an Independent Trustee of Ishares Dow Jones US Pharmaceuticals Index Fund since 2005. Ms. Herbert has served as a Director of iShares, Inc. since 2005 and a Director of iShares MSCI Russia Capped Index Fund, Inc. since 2010. She is Director of the Board of the Catholic Charities CYO, among the Bay Areas private social services organizations serving the homeless, poor, aged, families, children and AIDSHIV victims, on which she has served since 1998. Ms. Herbert is a member of the Finance Council, Archdiocese of San Francisco since 1994, which she chaired from 1994 to 2005. She is a Trustee of the Thacher School since 2002 and chairs its Investment Committee. She has served on numerous nonprofit boards. Ms. Herbert is also a Director and Advisory Board Member since 2009 of the Forward Funds. Ms. Herbert previously served as a Trustee for the Pacific Select Funds and The Montgomery Funds. Ms. Herbert previously served as Managing Director of J.P. MorganMorgan Guaranty Trust Company responsible for product development, marketing and credit for U.S. multinational corporations and as head of its San Francisco office and as Assistant Vice President, Signet Banking Corporation
| Age | 67 |
| Tenure | 20 years |
| Professional Marks | MBA |
| Issuer | iShares |
| Inception Date | 2006-05-01 |
| Benchmark | Dow Jones U.S. Select Pharmaceuticals Index |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 610.64 Million |
| Average Trading Valume | 79,088 |
| Asset Type | Equity |
| Category | Sector |
| Focus | Health Care |
| Market Concentration | Developed Markets |
Similar Fund Executives
| Showing other executives | One Year Return | ||
| Madhav Rajan | iShares Healthcare ETF | 52 | |
| John Martinez | iShares Healthcare ETF | 55 | |
| Scott Zoltowski | SPDR SP Pharmaceuticals | 43 | |
| Philip Nussbaum | Invesco Dynamic Pharmaceuticals | 51 | |
| Ronn Bagge | Invesco Dynamic Pharmaceuticals | 54 | |
| Charles Hurty | iShares Healthcare ETF | 72 | |
| John Kerrigan | iShares Insurance ETF | 60 | |
| Robert Kapito | iShares Insurance ETF | 61 | |
| Madhav Rajan | iShares Insurance ETF | 52 | |
| Kevin Gustafson | Invesco Dynamic Pharmaceuticals | 42 | |
| Eilleen Clavere | iShares Healthcare ETF | 60 | |
| Charles Hurty | iShares Insurance ETF | 72 | |
| Chad Hallett | SPDR SP Pharmaceuticals | 46 | |
| Mary Zeven | SPDR SP Pharmaceuticals | 51 | |
| John Clark | SPDR SP Pharmaceuticals | 45 | |
| Eilleen Clavere | iShares Insurance ETF | 60 | |
| Donald Wilson | Invesco Dynamic Pharmaceuticals | 54 | |
| Frank Nesvet | SPDR SP Pharmaceuticals | 68 | |
| Helen Peters | SPDR SP Pharmaceuticals | 71 | |
| Robert Silver | iShares Healthcare ETF | 57 | |
| Dave Kelly | SPDR SP Pharmaceuticals | N/A | |
iShares Pharmaceuticals Money Managers
| Geoffrey Flynn, Chief Operating Officer, Executive Vice President | ||
| Robert Silver, Independent Trustee | ||
| John Kerrigan, Independent Trustee | ||
| Madhav Rajan, Independent Trustee | ||
| Matt Tucker, Vice President | ||
| Cecilia Herbert, Independent Trustee | ||
| Michael Latham, President Trustee | ||
| Jack Gee, Chief Financial Officer, Treasurer | ||
| Charles Hurty, Independent Trustee | ||
| Eilleen Clavere, Secretary | ||
| George Parker, Independent Chairman of the Board of Trustees | ||
| John Martinez, Independent Trustee | ||
| Amy Schioldager, Executive Vice President | ||
| Robert Kapito, Trustee | ||
| Ira Shapiro, Vice President Chief Legal Officer |
IShares Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is IShares Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Earning | 22.36 X | |||
| Price To Book | 1.56 X | |||
| Price To Sales | 3.32 X | |||
| Number Of Employees | 15 | |||
| Beta | 0.59 | |||
| Total Asset | 381.08 M | |||
| One Year Return | 6.50 % | |||
| Three Year Return | 1.60 % | |||
| Five Year Return | 6.10 % | |||
| Ten Year Return | 4.20 % |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Pharmaceuticals ETF. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
The market value of iShares Pharmaceuticals is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is IShares Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Pharmaceuticals' market value can be influenced by many factors that don't directly affect IShares Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.